Trial Profile
A Single-centre, Randomized, Double-blind (Sponsor Unblinded), Placebo-controlled Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 2982772 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 24 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Dec 2015 Planned number of patients changed from 72 to 76, according to ClinicalTrials.gov record.
- 18 Dec 2015 Planned End Date changed from 1 Sep 2015 to 1 Feb 2016 , according to ClinicalTrials.gov record.